Differential expression of epithelial-mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer by Pomp, Victoria et al.








Differential expression of epithelial-mesenchymal transition and stem cell
markers in intrinsic subtypes of breast cancer
Pomp, Victoria ; Leo, Cornelia ; Mauracher, Andrea ; Korol, Dimitri ; Guo, Wenjun ; Varga, Zsuzsanna
Abstract: The transcription factors SLUG and SOX9 have been shown to define mammary stem cell state.
Similarly, epithelial-mesenchymal transition (EMT) markers (E-Cadherin, mTOR) have been shown to
play a role in tumor-progression and metastatic potential in breast cancer. Finally, SOX10 is known to
be expressed in breast cancer as well. The overexpressions of EMT and stem cell markers have been
shown to correlate with poor overall survival. In this study, we examined whether the expression of these
markers correlates with intrinsic subtypes of breast cancer and whether there is a prognostic difference
in their expression-profile. We analyzed 617 breast cancer samples from two tissue micro arrays. Breast
cancer samples were categorized into three groups according to hormone receptor expression and HER2-
status as Luminal A/B, HER2-positive, and triple negative subgroup. Immunohistochemical expressions
of SLUG, SOX9, SOX10, E-Cadherin, and mTOR were semi-quantitatively analyzed using a two-tiered
and three-tiered scoring system in which cytoplasmic and nuclear stains were considered. Strong nuclear
expression of SLUG was observed preferentially in triple negative but not in Luminal A/B or HER2-
positive cases (24 vs. 3 and 0 %, p < 0.001). Loss of SOX9 in the nuclear stain was less frequent in
triple negative than in Luminal A/B or HER2-positive cases (4 vs. 9 vs. 13 %, p < 0.001). Expression of
nuclear SOX10 was lower in triple negative than in Luminal A/B and HER2-positive cases (67 vs.78 and
79 %, p = 0.012). E-Cadherin loss was observed only in Luminal A/B tumors (p = 0.016), no difference
in the mTOR expression was seen between any of the three groups. No correlation to conventional
histopathological-parameters or stage could be established in our cohort. Our study shows an inversed
preferential nuclear expression of SLUG, SOX10, and SOX9 in triple negative and non-triple negative
cases. This information is important in understanding the biology of triple negative breast cancer, also
in terms of future studies dealing with targeted therapies based on the alterations of EMT and stem cell
markers.
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Abstract The transcription factors SLUG and SOX9
have been shown to define mammary stem cell state.
Similarly, epithelial–mesenchymal transition (EMT)
markers (E-Cadherin, mTOR) have been shown to play a
role in tumor-progression and metastatic potential in breast
cancer. Finally, SOX10 is known to be expressed in breast
cancer as well. The overexpressions of EMT and stem cell
markers have been shown to correlate with poor overall
survival. In this study, we examined whether the expression
of these markers correlates with intrinsic subtypes of breast
cancer and whether there is a prognostic difference in their
expression-profile. We analyzed 617 breast cancer samples
from two tissue micro arrays. Breast cancer samples were
categorized into three groups according to hormone
receptor expression and HER2-status as Luminal A/B,
HER2-positive, and triple negative subgroup. Immunohis-
tochemical expressions of SLUG, SOX9, SOX10, E-Cad-
herin, and mTOR were semi-quantitatively analyzed using
a two-tiered and three-tiered scoring system in which
cytoplasmic and nuclear stains were considered. Strong
nuclear expression of SLUG was observed preferentially in
triple negative but not in Luminal A/B or HER2-positive
cases (24 vs. 3 and 0 %, p\ 0.001). Loss of SOX9 in the
nuclear stain was less frequent in triple negative than in
Luminal A/B or HER2-positive cases (4 vs. 9 vs. 13 %,
p\ 0.001). Expression of nuclear SOX10 was lower in
triple negative than in Luminal A/B and HER2-positive
cases (67 vs.78 and 79 %, p = 0.012). E-Cadherin loss was
observed only in Luminal A/B tumors (p = 0.016), no
difference in the mTOR expression was seen between any
of the three groups. No correlation to conventional
histopathological-parameters or stage could be established
in our cohort. Our study shows an inversed preferential
nuclear expression of SLUG, SOX10, and SOX9 in triple
negative and non-triple negative cases. This information is
important in understanding the biology of triple negative
breast cancer, also in terms of future studies dealing with
targeted therapies based on the alterations of EMT and
stem cell markers.
Keywords Intrinsic subtypes  Breast cancer  Stem
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Introduction
The various intrinsic subtypes of breast cancer have been
receiving increased attention in stratifying breast cancer,
especially in terms of prognostic and predictive informa-
tion to aid clinical decision making [4, 7]. Although
prognosis and therapeutic options for breast cancer have
considerably improved over the last decade, intrinsic sub-
types, such as triple negative breast cancer (TNBC) still
have a poor prognosis [4, 7]. Several recent studies have
addressed the role of epithelial–mesenchymal transition
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(EMT) factors and stem cell markers in breast cancer, with
special emphasis on correlation to intrinsic subtyping [6, 9,
13, 16, 23]. Recently, Guo et al. described SLUG and SOX
9 as being mammary stem cell markers [9]. A change in the
activation status of this gene couple leads to a tumorigenic
progression of beast cells and to inhibition of the metastatic
process [2, 9]. Furthermore, these markers can induce
epithelial to mesenchymal phenotype in patients with early
breast cancer onset [9, 23]. This is important as EMT has
been described playing a role in the transition of cells to a
stem cell phenotype, which then can cause drug resistance
and tumor recurrence [16, 20, 23]. SLUG is part of the snail
family (SNAI2) and acts as a transcriptional repressor,
important in the regulation of transcription processes of
various genes and therefore also of protein synthesis in
cells [9, 21]. SOX9 on the other hand is a highly mobile
transcription factor that plays a pivotal role in EMT in cells
during embryogenesis [3]. Other SOX genes, such as
SOX10, along with SOX9, are located in the sex determine
region Y (SRY) [9, 21, 23].
SOX9 and SOX 10 are nuclear transcription factors with
a High Monility Group (HMG) DNA-binding domain [3,
6]. Originally, SOX10 was discovered as survival mediat-
ing factor for neural crest cells allowing their differentia-
tion into melanocytes and glia cells [6, 13]. Recently,
SOX10 has been found in TNBC as well as in salivary
gland tumors, especially in cells with a myoepithelial dif-
ferentiation [6, 13].
E-Cadherin is a transmembrane cell adhesions protein
usually expressed in luminal breast cells with epithelial
differentiation [11, 22]. The loss of E-Cadherin has been
considered as a step for cancer cells to acquire a mes-
enchymal status in order to enter the EMT [16]. SLUG ties
into this as it is one of several transcription factors involved
in EMT that can downregulate the E-Cadherin expression
[11]. The clinical importance of these factors was described
by Choi et al. [5]. They found a significantly higher rate of
EMT expression as well as a loss of E-Cadherin in invasive
basal-like breast cancer [5].
The protein mTOR plays an important role in cell
metabolism as well as in tumor development and growth
and constitutes one part of the mammalian target of the
Rapamycin (mTOR)/phosphoinositide 3 kinase (PI3K)
pathway [19, 25]. Resistance to endocrine therapy has been
attributed to the PI3K/mTOR pathway in estrogen receptor
positive (ER?) breast cancer caused by an alternative
activation of the usually hormone-dependent pathway [19,
25]. Furthermore, an active PI3K/mTOR pathway has been
described to mediate resistance to Trastuzumab in HER2-
positive breast cancer. The mesenchymal-like subtype in
the TNBC group seems to benefit from the activation of
this pathway due to its responsiveness to drugs targeting
mTOR [25].
In our study, we addressed the question, whether EMT
and stem cell markers are differentially expressed in the
intrinsic subtypes of breast cancer and what prognostic
information these expression profiles have.
We systematically analyzed the above described panel
of EMT and stem cell markers in a large cohort of breast
cancer samples. These were divided into the intrinsic breast
cancer subtypes as Luminal A/B, HER2-positive, and
TNBC. We analyzed the protein expression of these
markers using semiquantitative immunohistochemical
scores and linked the scores to the intrinsic phenotype as
well as to three traditional clinico-pathological parameters
as grading, staging, and overall survival.
Materials and methods
Patient cohort
Altogether 617 breast cancer patients were included in this
study. Tissue cores from archived formalin-fixed in paraf-
fin-embedded tumors blocks containing invasive carcinoma
from two tissue micro arrays (TMA) were used for the
study. The cohort encompassed samples from the Institute
of Surgical Pathology of the University Hospital Zurich
between 1991 and 2011. Primary tumor tissue was avail-
able in n = 565 cases, tumor tissue from recurrent lesions
in n = 45 cases, and tissue from lymph node metastasis in
n = 7 cases. All patients underwent either a mastectomy or
a segmentectomy.
All clinico-pathological data and most of the data on
patient survival were collected from the database of the
Institute of Surgical Pathology, University Hospital Zurich.
Follow-up information was additionally available through
the Cancer Registry of the Canton Zurich.
This study is a part of a larger breast cancer study, which
was previously approved by the Ethical Committee of the
Canton Zürich (KEK-ZH NR: 2012-0553) and also by the
internal review board of the Institute of Surgical Pathology,
University Hospital Zurich.
Definition of intrinsic subtypes
The patients were grouped into three molecular subtypes
based on definition in the literature as follows [26, 27]:
1. Triple negative phenotype (TNBC): All tumors with a
negative estrogen and progesterone receptor status
(\1 %) and negative HER 2 status (assessed either by
immunohistochemistry and/or fluorescent in situ
hybridization (FISH)).
2. Luminal A/B: All tumors with positive estrogen
receptor ([1 %) and positive/or negative progesterone
receptor status and positive/or negative HER2 status.
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3. HER2 positive tumors: All tumors with a positive
HER2 Status (either being scored 3? by immunohis-
tochemistry and/or amplified by FISH) and a negative
hormone receptor status.
The hormone receptor and HER2 status of the invasive
tumor tissue was taken from the original pathology reports.
In total, we included n = 120 triple negative, n = 457
Luminal A/B, and n = 40 HER2positive cases in this
study.
Clinic-pathological parameters
All clinico-pathological parameters are shown in Tables 1, 2.
The age of our patient cohort ranged from 21 to 91 years
of age. The lowest mean age was found in the HER2 group
with 53.9 years followed by the TN group with 55.5 years.
The highest mean age was found in the Luminal A/B
Group with 58.5 years.
In total, primary tumor tissue was available from 565
patient (TN n = 116, Luminal A/B n = 415, HER2 posi-
tive n = 34), tissue from a local recurrence was available
in 45 cases (TN n = 4, Luminal A/B n = 37, HER2-pos-
itive n = 4), and axillary lymph node metastasis were
available in 7 cases (TN n = 0, Luminal A/B n = 5,
HER2-positive n = 2).
Altogether n = 454 tumors were diagnosed as invasive
ductal carcinomas (TN n = 93, Luminal A/B n = 325,
Table 1 Clinical-pathological
parameters of the breast cancer
cohort, stratified according to
intrinsic subtype
n = 617 TNBC Luminal A and B HER2 positive
120 457 40
n % n % n %
Tissue
Primary tumor 116 97 415 91 34 85
Tumor recurrence 4 3 37 8 4 10
Lymphnode metastasis 0 0 5 1 2 5
Histological subtype
Invasive ductal 93 78 325 71 36 90
Invasive lobular 5 4 64 14 0 0
Other 19 16 47 10 3 8
Not known 3 2 21 5 1 2
Grade
G1 0 0 81 18 2 5
G2 13 11 244 53 7 18
G3 104 87 107 23 30 75
Not known 3 2 25 5 1 2
Stage: pT
pT1 40 33 184 40 19 48
pT2 63 54 197 43 13 33
pT3 9 7 33 7 5 12
pT4 5 4 22 5 2 5
Not known 3 2 21 5 1 2
Stage: pN
pN0 57 47 139 30 15 38
pN1 35 29 195 43 15 38
pN2 14 12 35 8 1 2
pN3 7 6 22 5 6 15
Not known 7 6 66 14 3 7
Stage M
M0 57 48 398 87 30 75
M1 28 23 14 3 4 10
Not known 35 29 45 10 6 15
TNBC triple negative breast cancer
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HER2 positive n = 36) and n = 69 carcinomas were
classified as an invasive lobular subtype (TN n = 5,
Luminal A/B n = 64, HER2 positive n = zero). Special
subtypes such as medullary carcinoma, secretory carci-
noma, and others were diagnosed in a separate category,
which contained n = 69 cases (TN n = 19, Luminal A/B
n = 47, HER2 positive n = 3). This information was
deduced from the pathological diagnosis report and was
missing from the database for 22 patients.
Grading was available in n = 588 cases according to the
modified Bloom and Richard grading score. 241 of 588
cases were poorly differentiated (G3: TN n = 104, Lumi-
nal A/B n = 107, HER2 positive n = 30), 264 of 588 cases
were moderately differentiated (G2: TN n = 13, Luminal
A/B n = 244, HER2 positive n = 7), and 83 of 588 cases
were well differentiated (G1: TN n = 0, Luminal A/B
n = 81, HER2 positive n = 2).
Tissue Microarrays
Two tissue microarrays were used in this study. The first
tissue micro array (TMA 21) contained 544 single spots
from all three subtypes, which were collected from 1991 to
2004. One spot per patient tissue sample was represented in
this TMA. The second tissue micro array (TMA 174)
contained 73 TNBC cases in double cores from the years
2005 to 2011.
The method of constructing these TMA-s from archived
formalin-fixed, paraffin-embedded tumor blocks have been
previously described [14, 24].
Immunohistochemistry
E-Cadherin
The clone EP700Y (Cell Marque Lifescreen Nr 246R-16)
was used. Dilution 1:2000, with pretreatment with CC1 for
40 min and visualized with the OptiView kit from Ventana
on the Ventana autosstainer.
mTOR
The clone 7C10 (CellSignaling Nr 2983) was used. Dilu-
tion: 1:50, pretreatment H2 for 45 min, visualized by the
Refine HRP kit on the Leica/Zeiss Bond autostainer.
SLUG
The clone SLUG Klon C19G7 (Cell Signaling Nrl 9585)
was used. Dilution 1:50, pretreatment in CC1 for 60 min,
visualized by ChromoMapDAB ? UltraMap Rabbit on the
Ventana autostainer.
SOX9
The clone Sox9 Polyklonal (Millipore Nr. AB5535) was
used. Dilution: 1:4000, pretreatment CC1 for 48 min,
visualized with the OptiView kit from Ventana on the
Ventana autostainer.
SOX10
The clone BC34 (Biocare Medical Nr. ACI3099) was used,
Dilution 1:150, pretreatment H2 in 20 min, visualized by
the Refine HRP kit on the Leica/Zeiss Bons stainer.
Scoring of immunohistochemical stains
We used a two-tiered (negative vs. positive) and a three-
tiered (negative, mildly positive meaning \50 % of the
cells are positive, and strongly positive meaning[50 % of
the cells positive) scoring system.
The expressions in tumor cells of E-Cadherin and
mTOR were scored with a two-tired system (negative vs.
positive).
The nuclear expressions of SLUG, SOX 9, and SOX 10
in tumor cells were scored with a three-tired system. The
cytoplasmic reaction of SLUG and SOX 10 was deter-
mined with a two-tiered system.
Illustrative photographs are shown in Figs. 1 and 2.
Statistical analysis
IBM SPSS Statistics 20 was used for the database and for
the frequency evaluation in order to compare the TNBC
group to the other two subtype groups. The frequency
distribution probability was calculated by two-tailed Fish-
er’s exact test with 2 9 3 or 2 9 2 contingency tables.
Kaplan–Meier curves were used for a correlation analysis
of markers and 5-year overall survival. Statistical signifi-
cance was evaluated by log rank test. Overall, a p value of
under 0.05 was determined as being statistically significant.
Table 2 Age of the patients stratified according to intrinsic subtypes
of breast cancer
TNBC Luminal A and B HER2 positive
Age (in years)
Mean 55.5 58.5 53.9
Median 54.5 59.0 53.0
Minimum 27 28 22
Maximum 88 91 87
Not known 0 127 11
TNBC triple negative breast cancer
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Results
Nuclear expressions of SLUG, SOX9, and SOX10
SLUG showed a differential nuclear expression in the three
subtypes. In the TNBC group, we found 24 % strongly
positive, 40 % mildly positive and 36 % negative cases.
Strongly positive cases were seen in 3 % of Luminal
A/B and in 0 % in HER2? positive cases. Mildly positive
scored cases were seen in 49 % of Luminal A/B and 45 %
of HER2 positive group. Negative stains were seen in 55 %
of HER2-positive and 48 % of Luminal A/B cases.
Upon comparison of all three groups, the differences in the
strong nuclear stain were statistically significant (p\0.001).
SOX 9 expression was different in all three subtypes. A
strong nuclear expression was seen in 88 % of TNBC, in
65 % of Luminal A/B and 67 % of HER2 positive tumors.
Mild nuclear stain was seen in 8 % of TNBC, 26 % of
Luminal A/B cases, and 20 % of HER2 positive cases. A
lack of expression was found in 4 % of TNBC cases, 9 %
of Luminal A/B, and 13 % of HER2 positive cases.
The differences within the strong nuclear stains were
statistically significant between the three groups (TN vs.
Luminal A/B p\ 0.001, TN vs. HER2-positive
p = 0.011).
SOX10 was expressed differently in the three groups.
Strong nuclear expression was common in the Luminal
A/B (78 %) and the HER2-positive groups (79 %) than in
the TNBC (67 %) cases. Mild positivity was more common
in TNBC (31 %) than in Luminal A/B (21 %) and HER2
positive (14 %) cases. Negative stains were found in 7 %
of HER2 positive cases, in 2 % of TNBC and in 1 %
Luminal A/B tumors. A significant difference was found
(p = 0.038) when comparing TNBC to Luminal A/B
subgroup. On the other hand, difference in protein
expression between TNBC and HER2-positive groups was
nearly significant (p = 0.06). Finally, comparing all three
groups, protein expression was significantly different
(p = 0.012).
Cytoplasmic Reaction of SLUG and SOX 10
The SLUG cytoplasmic stain was equal in all three sub-
types: 94 % of TNBC and of Luminal A/B, and 95 % of
HER2 positive cases expressed cytoplasmic SLUG (no
significant difference).
SOX 10 cytoplasmic positivity was similar in all three
groups: 97 % of TNBC cases, 96 % of HER2 positive
cases, and 93 % of Luminal A/B cases (no significant
difference).
Fig. 1 Immunohistochemical expressions of E-Cadherin and mTOR in tissue microarrays scored with a two-tiered system for transmembrane
expression
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E-Cadherin expression
E-Cadherin positivity was more frequent in TNBC (114 of
120 cases) (95 %) than in Luminal A/B subgroup (378 of
439 cases) (86 %), this difference was statistically signifi-
cant (p = 0.006).
No difference in E-Cadherin expression was found
between the TNBC and HER2 positive groups (p = 0.26).
mTOR expression
mTOR was similarly expressed in all three subgroups:
78 % of TNBC and Luminal A/B and 74 % of HER2-
positive cases expressed mTOR (p = 0.76 comparing all
three subgroups).
Results are shown in detail in Tables 3 and 4 and in
Figs. 3 and 4.
Correlation of E-Cadherin, mTOR, SLUG, SOX9,
SOX10 expressions and 5-year overall survival
The correlation of overall survival with the EMT and stem
cell markers was quantified using Kaplan–Meier curves in
all three subgroups. No significant correlation could be
seen in any of the analyzed markers. The 5-year survival
was evaluated in the TNBC subgroup as well but no sig-
nificant correlation was found there either.
Results are shown in detail in Table 5.
Correlation of E-Cadherin, mTOR, SLUG, SOX9,
SOX10 expressions and histological grade
and tumor stage
SOX10 positive cytoplasmic expression correlated with the
histological grade (G3) in the HER2-positive group
(Pearson Chi-square p = 0.001).
Fig. 2 Immunohistochemical expressions of SLUG, SOX9, and SOX10 in tissue microarrays scored with a three-tired system for nuclear
expression. Cytoplasmic expression was assessed of SLUG and SOX10 with a two-tiered scoring system
50 Breast Cancer Res Treat (2015) 154:45–55
123
SLUG nuclear expression similarly correlated with the
histological grade (G3) in the HER2-positive group
(Pearson Chi-square p = 0.023) as well as in the Luminal
A/B group (Pearson Chi-square p = 0.008).
SLUG cytoplasmic stain correlated with tumor stage (pT2)
in the triple negative group (Pearson Chi-square p = 0.004).
SOX9 nuclear expression correlated with the histologi-
cal grade (G2/3) in the Luminal A/B group (Linear asso-
ciation p = 0.035) and with tumor stage (pT2) in the triple
negative group (Pearson Chi-square p = 0.019).
No correlation between the nodal stage and the intrinsic
subtype could be detected.
Discussion
In our study, we compared the protein expression profiles
of EMT and stem cell markers in a cohort of breast cancer
samples and looked for a correlation between expression
profiles in TNBC, Luminal A/B, and HER2 positive
intrinsic subgroups. We could show that EMT and stem
cell markers are differentially expressed in these three
intrinsic subtypes of invasive breast cancer. The TNBC
intrinsic phenotype significantly differed in nuclear SLUG,
SOX10, and SOX9 expressions from the Luminal A/B and
HER2-positive subgroups. Preserved nuclear SLUG and
nuclear SOX9 expressions as well as loss of nuclear
SOX10 was a more common finding in TNBC, when
comparing expression profiles with Luminal A/B and
HER2-positive groups. The Luminal A/B subgroup sig-
nificantly differed from TNBC and HER2-positive cases
with regards to the loss of E-Cadherin, while mTOR
expression did not differ in the three intrinsic subtypes of
our cohort.
Markers defining EMT and the stem cell phenotype in
breast cancer have increasingly been the focus of attention
in breast cancer research, as these factors have been
described to influence tumor growth as well as metastatic
properties of breast cancer [9, 17, 18]. Inhibition of EMT
factors as an approach in the targeted therapies in TNBC
has become an active field of basic research [8, 12]. The
fact that a strong nuclear SLUG is virtually missing in the
HER2-positive cases of our cohort, needs further valida-
tion. In a recent study, a strong correlation between HER2-
Table 3 Expressions of EMT and stem cell markers in a two-tiered scoring system
N = 617 TNBC Luminal A&B Her2? ER- p-value comparing
all groups*
120 457 40
n Valid % n Valid % n Valid %
E-Cadherin 0.018
Positive 114 95 378 86 35 90
Negative 6 5 61 14 4 10
Missing 0 18 1
p-value TN versus this group** 0.006 0.261
mTOR 0.763
Positive 93 78 327 78 26 74
Negative 26 22 88 22 9 26
Missing 1 42 5
p-value TN versus this group** 0.899 0.649
SLUG cytoplasmic stain
Positive 113 94 420 94 38 95 1
Negative 7 6 25 6 2 5
Missing 0 33 0
p-value TN versus this group** 1 1.0
SOX 10 cytoplasmic stain 0.527
Positive 115 96 347 93 28 97
Negative 5 4 27 7 1 3
Missing 0 83 11
p-value TN versus this group** 0.291 1
* Two-tailed Fisher’s exact test with 2 9 3 contingency tables to calculate frequency distribution probability between all 3 groups
** Two-tailed Fisher’s exact test with 2 9 2 contingency tables to calculate frequency distribution probability between TN and one other
Subgroup
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positive cell lines and induction of an EMT status was
reported [10]. Furthermore, drug resistance in a SLUG
positive cell line via binding to the ER promoter was also
recently described [15].
Strongly maintained nuclear SLUG expression as a main
finding in TNBC but not in Luminal A/B and HER2-pos-
itive samples corresponds well to what has been described


























Fig. 3 Nuclear expressions of
SLUG, SOX9, and SOX10 in a
three-tiered scoring system
(scores are shown in
percentages)
Table 4 Expressions of EMT and stem cell markers in three-tiered scoring system
N = 617 TNBC Luminal A/B Her2? ER- p-value comparing
all groups*
120 457 40
n Valid % n Valid % n Valid %
SLUG nuclear stain \0.0001
Strong positive 29 24 13 3 0 0
Light positive 48 40 220 49 18 45
Negative 43 36 212 48 22 55
Missing 0 12 0
p-value TN versus this group** 0.000 0.0003
SOX 9 nuclear stain \0.0001
Strong positive 105 88 289 65 26 67
Light positive 10 8 118 26 8 20
Negative 5 4 39 9 5 13
Missing 0 11 1
p-value TN versus this group** 0.000 0.011
SOX 10 nuclear stain 0.012
Strong positive 81 67 294 78 23 79
Light positive 37 31 78 21 4 14
Negative 2 2 3 1 2 7
Missing 0 82 11
p-value TN versus this group** 0.038 0.060
* Two-tailed Fisher’s exact test with 3 9 3 contingency tables to calculate frequency distribution probability between all 3 groups
** Two-tailed Fisher’s exact test with 2 9 3 contingency tables to calculate frequency distribution probability between TN and one other
Subgroup
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regarding expression of stem cell markers including SLUG
could not be linked to a poor prognosis, however SLUG
expression together with one further transcription factor,
ALDH1 was associated with shorter disease-free survival
[12]. Similarly to our own observation, one further study
by Alkatout et al., found no correlation between SLUG or
other respective EMT markers and clinical outcome [1].
Higher levels of cytoplasmic SOX9 expression have
been described as being present more commonly in TNBC
than in other subtypes and a correlation of this expression
with higher histological grade and poorer survival has also
been reported [3, 9, 21]. We obtained similar results as we
found the nuclear positivity of SOX9 to be more strongly
positive in TNBC than in other subtypes, TNBC cases
being mainly G3 in our cohort. The correlation of SOX9
expression to higher histological grade could be also con-
firmed in LumA/B cases in our cohort [3]. Nevertheless, no
prognostic value was found in the nuclear/or cytoplasmic
expression of SOX9 in our cohort when looking at overall
or 5-year survival.
SOX10 nuclear expression was independently found to
be more frequent in TNBC and basal-like breast cancer in
two earlier studies [6, 13]. Our study showed that strong
nuclear expression of SOX10 was similarly present in
TNBC, Luminal A/B, and HER2-positive cases. However
there was a significant difference in the detection of mild
positivity or loss of a nuclear stain, this was more fre-
quently detected in the HER2 positive group than in the
TNBC or Luminal A/B cases of our cohort. Our results
further support the hypothesis, that SOX10 expression is a
common finding in cancer exhibiting myoepithelial and
basal differentiation [6, 13]. Nevertheless, the biological
importance of the loss in SOX10 expression in HER2
positive breast cancer is currently not fully understood.
Differences to previous studies regarding the lack of an
association between markers and overall survival in our





















Fig. 4 Expressions of
E.Cadherin and mTOR in a two-
tiered scoring system (scores are
shown in percentages)
Table 5 Results of Kaplan–
Meier curves Log Rank
(Mantel–Cox) significant test in
overall survival and in 5-year
survival in terms of expressions
of EMT and stem cell markers
E-Cadherin mTor Slug nuclear SOX 9 SOX 10
Overall survival
TNBC 0.541 0.752 0.682 0.311 0.620
Luminal A&B 0.784 0.387 0.404 0.142 0.575
HER2? 0.659 0.785 0.529 0.292 0.677
5-year survival
TNBC 0.373 0.779 0.676 0.319 0.565
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study can be partially explained by possible intra-tumoral
heterogeneity. The fact, that two tissue cores were avail-
able in the TNBC cases, and only one tissue core from the
other groups in our study, can be considered as one further
factor in increasing intra-tumoral heterogeneity.
E-Cadherin, as a hall-mark in the process of EMT was
almost equally present in the TNBC and HER2 positive
group, providing no further prognostic information on
these subgroups in our cohort. This result contradicts ear-
lier findings where the loss of E-Cadherin was more
commonly detected in the invasive basal-like phenotype
[5]. The increased loss of E-Cadherin in the Luminal A/B
subgroup of our study can be explained by the higher
frequency of an invasive lobular phenotype in this group,
typically being hormone receptor positive than of a basal-
like phenotype.
The expression of mTOR, which is a part of the PIK3K/
Akt/mTOR pathway and has been well established to
influence tumor growth, could not be differentiated using
the the intrinsic subtypes in our study [19]. This result
corresponds to the described presence of the mTOR path-
way in all there subtypes by Vicient et al. [25]. mTOR
inhibitors, such as Everolimus, are being considered in the
treatment of hormone receptor positive and HER2-negative
and metastatic or locally advanced breast cancer [19].
Conclusion
Our data show evidence, that stem cell and EMTmarkers are
differentially expressed in the basic intrinsic subtypes of
breast cancer, being preferentially preserved in TNBC.
Despite lack of correlation to prognosis in our study, this data
may serve as additional information in evaluating targeted
therapies based on the alterations of EMT and stem cell
markers. Further studies will be needed to identify the exact
prognostic role of EMT and stem cell markers, when strat-
ifying breast cancer according to intrinsic subtypes.
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